Literature DB >> 27133231

Introduction of Inactivated Poliovirus Vaccine in National Immunization Program and Polio Endgame Strategy.

Vipin M Vashishtha1, Jaydeep Choudhary, Sangeeta Yadav, Jeeson C Unni, Pramod Jog, Sachidanand S Kamath, Anupam Sachdeva, Sanjay Srirampur, Baldev Prajapati, Bakul J Parekh.   

Abstract

The World Health Organization declared India among other 10 countries in South East Region - as 'polio-free' in 2014. Since then, the Government of India (GoI) has scaled up its initiatives against polio endgame which targets virus eradication and sequential withdrawal of type 2 virus from oral polio vaccine (OPV). However, prior to choosing the switch from trivalent OPV (t-OPV) to bivalent OPV (b-OPV), it was suggested to include inactivated poliovirus vaccine (IPV) in the national immunization schedule to protect vaccine naïve population against type 2 poliovirus. The GoI declared introduction of single dose of intramuscular IPV at 14 weeks since October 2015. In addition, anticipating the scarcity of IPV at present in India, GoI also recommended two intradermal doses of IPV in few states since April 2016. This review discusses the programmatic implications of these strategies along with recommendations by the Advisory Committee on Vaccines and Immunization Practices of Indian Academy of Pediatrics (IAP-ACVIP) on polio endgame strategy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27133231

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  2 in total

1.  Distribution pattern of poliovirus potentially infectious materials in the phase 1b medical laboratories containment in conformity with the global action plan III.

Authors:  Bassey Enya Bassey; Fiona Braka; Faisal Shuaib; Richard Banda; Sisay Gashu Tegegne; Johnson Muluh Ticha; Walla Hamisu Abdullalhi; Olatunji Mathew Kolawole; Yusuf Kabir
Journal:  BMC Public Health       Date:  2018-12-13       Impact factor: 3.295

2.  Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study.

Authors:  S Mangarule; S Prashanth; A Kawade; M D Ravi; I V Padmavathi; S Palkar; V N Tripathi; R Singh; M Maurya; M Mitra; R S Shetty; R Z Kompithra; S M Dhaded; V Epari; A Moureau; M V Jayanth; K Varghese; S Ravinuthala; D Kukian; B N Patnaik; F Noriega
Journal:  Vaccine X       Date:  2022-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.